THE UBIQUITIN PROTEASOME SYSTEM (UPS)

The role of protein turnover mediated by the ubiquitin proteasome system (UPS) in neuronal plasticity and memory has been studied for about two decades. Here we will only briefly summarize the basic functioning of this system that has been described in more detail in several reviews (Ciechanover, 2005; Patrick, 2006; Hegde, 2010; Mabb and Ehlers, 2010; Bingol and Sheng, 2011). The UPS controls the degradation of misfolded newly synthesized proteins as well as the turnover of specific target proteins. Its function can be described as a two-step process: the tagging of target proteins and their degradation. Ubiquitin molecules can be attached one to another and form a poly-ubiquitin chain which acts as a specific tag to direct proteins to proteasome-dependent degradation (Figure 1A). This enzymatic linkage is dependent on the activity of three types of enzymes: Ubiquitin-activating enzymes (E1), Ubiquitin-conjugating enzymes (E2), and Ubiquitin ligases (E3). E1 enzymes form a thioester bond with a ubiquitin molecule to activate it. The combined action of E2 and E3 enzymes then permits its linkage to a specific target protein. E3 enzymes mark the proteins that have to be degraded with a poly-ubiquitin chain (linked through Lysine 48 residues) but can also mediate mono- or other types of polyubiquitination to affect different processes such as protein trafficking and kinase activation (see Bingol and Sheng, 2011 for a more detailed description). Another important class of enzymes is also involved in the regulation of poly-ubiquitination and UPS activity: the desubiquitinating enzymes (DUBs). They oppose the action of E3 ligases by removing ubiquitin. Thus, E1, E2, E3, and DUB enzymes tightly regulate the addressing of proteins to the proteasome. The second step of UPS function relies on the proteolytic activity of the 26S proteasome. This complex of proteins can be sub-divided into two components: the 20S proteasome which is the catalytic core where degradation takes place and the 19S proteasome which acts as a regulatory complex. The 20S proteasome is made of two external and two internal rings of proteins. External rings are composed of seven alpha type proteins (numbered from α1 to α7). They are involved in the regulation of the access of tagged proteins to the inner core (internal rings) of the 20S proteasome. The internal rings are composed of seven beta type proteins (numbered from β1 to β7) which are responsible for the catalytic activity of the proteasome. Three subunits are directly involved in degradation processes: the β1, β2, and β5 subunits which are responsible for caspase-like, trypsin-like and chymotrypsin-like activity respectively. The other types of β subunits have been proposed to play a structural role in the complex and to be involved in the binding of targeted proteins during their degradation by β1, β2, and β5 subunits. Different complexes can be associated with the 20S proteasome, the 19S proteasome being the most frequent. The 26S proteasome possesses two 19S proteasome regulatory complexes located at each extremity of the 20S core. They can also be divided in two distinct subparts: the lid and the base. The lid is composed by 9 regulatory particle non-ATPase (Rpn) proteins and possesses two main roles: the recognition of poly-ubiquitinated proteins and the removal of ubiquitin from the targeted proteins. The base is composed of 10 proteins with or without ATPase activity, Regulatory
Massaly et al. Ubiquitin/proteasome and drug abuse

FIGURE 1 | The Ubiquitin Proteasome System and its components regulated after drug exposure. (A) Schematic representation of the Ubiquitin Proteasome System. The external and internal rings constitute the 20S proteasome. The lid and base constitute the 19S regulatory complex. In some cases, it can be replaced by the PA28 or 11S regulatory complex, constituted of a single ring of 7 subunits. (B) Classification of the UPS components found to be regulated after drug exposure.

particle ATPases (Rpt) and Rpn proteins respectively. It is physically connected to the proteasome 20S and is involved in the unfolding of proteins and the regulation of their entry into the catalytic core. Thanks to the combined actions of E1, E2, E3, and DUB enzymes and the 19S proteasome complex, the UPS can finely control the identity of the proteins to be targeted and degraded by the catalytic core located in the inner part of the 20S proteasome.

THE UPS IN NEURONAL PLASTICITY AND MEMORY

Changes in neuronal activity can result in the regulation of many proteins by the UPS. A descriptive study showed that increases or
decreases in the activity of cultured hippocampal neurons produce UPS-dependent changes in the amount of several proteins in post-synaptic densities (PSD), including proteins involved in PSD morphology, cytoskeleton organization and scaffolding of signaling complexes (Ehlers, 2003). This result suggests a close relationship between synaptic plasticity and protein degradation. Indeed, it has been reported that protein degradation by the UPS contributes to the formation and maintenance of long-term potentiation (LTP) and long-term depression (LTD). The first study reporting this involvement was conducted in Aplysia during induction of long-term facilitation (LTF) (Hegde et al., 1993). It demonstrated that regulatory subunits of the Protein kinase A (PKA) are targeted to the proteasome for degradation allowing prolonged action of PKA and Aplysia behavioral sensitization (Hegde et al., 1993). Later on, studies in rodents have shown that blocking the UPS in the hippocampus can alter N-methyl-D-aspartate (NMDA)- and/or metabotropic glutamate receptor (mGluR)-dependent LTD or LTP (Colledge et al., 2003; Citri et al., 2009). This deleterious effect of UPS blockade on long term changes in neurons has been suggested to be due to an alteration in the balance between protein synthesis and degradation (Fonseca et al., 2006). Indeed the authors showed that the deleterious effects produced by inhibiting either protein synthesis or degradation on LTP can be reversed by inhibition of the two processes at the same time. In addition to synaptic proteins the UPS is also involved in the regulation of the activity of transcription factors, thus revealing a close relationship between protein synthesis and proteasome action. For example IkB and CREM (cAMP-responsive element modulator), repressors of the transcription factors NF-kB and CREB (cAMP response element binding) respectively, can be ubiquitinated and degraded by the UPS (Woo et al., 2010; Liu and Chen, 2011). In that sense the UPS clearly plays a major role in the regulation of protein turnover implicated in neuronal plasticity acting directly through the degradation of some proteins and indirectly through the modulation of transcriptional activity and protein synthesis.

Unsurprisingly considering its role in neuronal plasticity, a strong involvement of UPS function has also been observed during learning and memory processes. These results are reported in detail in a recent review (Jarome and Helmstetter, 2014). More than 10 years ago a first study demonstrated the role of the proteasome in the dorsal hippocampus during the acquisition phase of inhibitory avoidance memory (Lopez-Salon et al., 2001). In this work the authors reported an increase in the rate of protein poly-ubiquitination in the hippocampus during training. They also found that the repressor of NF-kB, IκB, was present in this poly-ubiquitinated protein pool showing an involvement of the UPS in transcription factor activation. More recent studies confirmed the necessity of protein degradation in the hippocampus during consolidation and reconsolidation processes in rodents in spatial memory and fear conditioning (Artinian et al., 2008; Lee et al., 2008). The hippocampus is not the only region were proteasome activity is required for the creation and maintenance of memory. The involvement of protein degradation in both the prefrontal cortex and the amygdala during fear learning has also been demonstrated (Jarome et al., 2011; Reis et al., 2013). Proteasome action also appears to be necessary in both the insular cortex and the amygdala for aversive for drug abuse (Rodriguez-Ortiz et al., 2011).

The precise mechanisms underlying the involvement of the proteasome in memory are just beginning to be discovered but it is now clearly established that, in addition to protein synthesis, neuronal protein degradation by the UPS is a mandatory process to create, store and maintain memories and in that sense participates to adaptive behaviors of mammals. Since drug addiction shares common mechanisms with memory processes (Hyman et al., 2006; Milton and Everitt, 2012) it is important to question the role of the UPS in the long term effects of drugs of abuse such as opioids, stimulants, ethanol, nicotine and cannabinoids.

DRUGS OF ABUSE REGULATE THE UPS

In recent years, many transcriptomic and proteomic studies have described the global effects of treatments with drugs of abuse on the brain, or on neuronal or glial cell lines. Proteasome subunits or proteins involved in the ubiquitination process are often found to be regulated in these studies (Table 1, Figure 1B). In the case of opioids, it was shown in a cellular model that a prolonged 72 h morphine treatment modifies the abundance of two proteasome subunits (α3 and β6) (Neasta et al., 2006). In vivo, intra-cerebro-ventricular (icv) infusion of morphine for 72 h results in an increase in the tyrosine-phosphorylated form of the β4 subunit in the rat frontal cerebral cortex (Kim et al., 2005). A longer intermittent treatment (2 weeks) produces a decrease in the amount of the DUB Ubiquitin C-terminal hydrolase L-1 in the nucleus accumbens (Nacc) (Li et al., 2006). 4 days after morphine withdrawal, the quantity of this enzyme, as well as that of the α3 subunit of the proteasome, increases in rat dorsal root ganglia (Li et al., 2009). Similarly, chronic treatment (90 days) and drug withdrawal have been shown to have opposite effects on the amount of α5 subunit in the Nacc of rhesus monkeys (Bu et al., 2012). The levels of Ubiquitin-conjugating enzyme E2 and of Ubiquitin C-terminal hydrolase L-3 are also modulated in this model. Finally, in a morphine-induced conditioned place preference (CPP) paradigm which tests the rewarding properties of the drug, both development, extinction and re-instatement are accompanied by a down-regulation of several DUBs and α and β subunits (Lin et al., 2011).

Changes in expression of proteins of the UPS are not specific to opioid treatment. The amount of Ubiquitin C-terminal hydrolase L-1 is increased and that of RN3 (β7 catalytic subunit) is decreased in the striatum of rats acutely treated with methamphetamine while repeated injections induce an increase in Ubiquitin C-terminal hydrolase L-1 and a decrease in several proteasome subunits in the frontal cortex (Iwazaki et al., 2006; Faure et al., 2009; Kobeissy et al., 2009). The development of cocaine CPP comes with an increase in the expression of the Ubiquitin-conjugating enzyme E2N, of the catalytic α2 subunit and of the 26S proteasome regulatory subunit p45/SUG (Guan and Guan, 2013). Moreover, mouse cortical neurons grown in the presence of ethanol for 5 days show decreased amounts of mRNA coding for several ubiquitin-conjugating enzymes, as well as catalytic and regulatory subunits of the proteasome (Gutala et al., 2004) while the quantities of Ubiquitin C-terminal hydrolase L-1 decrease and
Table 1 | UPS-related molecular and cellular consequences of the treatment with drugs of abuse.

| Drug class | Drug          | Treatment               | Cell type/Species                  | Molecular/cellular effects                                                                 | Reference                      |
|------------|---------------|-------------------------|-----------------------------------|-------------------------------------------------------------------------------------------|--------------------------------|
| Opioids    | Morphine      | 72 h                    | Recombinant SH-SY5Y cells         | Change in α3 and β6 subunit abundance                                                     | Neasta et al., 2006           |
|            | Morphine      | 24 h                    | Recombinant SH-SY5Y cells         | UPS-dependent down-regulation of Gβ subunits of heterotrimeric G proteins                 | Mouledous et al., 2005        |
|            | DAMGO         | Overnight               | Human SH-SY5Y cells               | UPS-dependent down-regulation of RGS4                                                     | Wang and Traynor, 2011         |
|            | DADLE         | 40 min                  | Recombinant HEK cells             | MOP receptor ubiquitination                                                                | Hislop et al., 2011           |
| Basal turnover | N.A.       |                         | Recombinant NMB cells             | MOP receptor degradation by the UPS                                                       | Song et al., 2009              |
|            | Morphine      | 4h and 24 h             | Human SK-N-SM cells               | Modulation of proteasome catalytic activity                                                | Rambhia et al., 2005          |
|            | Morphine      | 48 h                    | Rat C6 glioma cells               | UPS-dependent down-regulation of EAAC1 glutamate transporter                              | Yang et al., 2008b            |
|            | Morphine      | 7 days intra-thecal     | Rat spinal cord                   | UPS-dependent down-regulation of EAAC1, GLAST, and GLT-1 glutamate transporters          | Yang et al., 2008a            |
|            | Morphine      | 72 h icv                | Rat frontal cortex                | Increase in Tyr-phosphorylated β4 subunit                                                 | Kim et al., 2005              |
|            | Morphine      | 2 weeks                 | Rat nucleus accumbens             | Decrease in Ubiquitin C-terminal hydrolase L1                                              | Li et al., 2006               |
|            | Morphine      | CPP                     | Rat amygdala                      | Decrease in α3, α6, β3, β4, β7 subunits, Ubiquitin C-terminal hydrolase L1 and Ubiquitin specific protease 7 | Lin et al., 2011             |
|            | Morphine      | 4 days after withdrawal | Rat dorsal root ganglia           | Increase in Ubiquitin C-terminal hydrolase L1 and α3 subunit                              | Li et al., 2009               |
|            | Morphine      | 4 days, increasing doses| Mouse striatum                    | Reduced UPS-dependent degradation of HSP70                                                 | Yang et al., 2014             |
|            | Morphine      | CPP                     | Mouse Nacc synaptosomes           | Increase in total protein ubiquitination                                                   | Massaly et al., 2013          |
|            | Morphine      | 90 days                 | Rhesus monkey Nacc                | Increase in α5 subunit and decrease in Ubiquitin conjugating enzyme E2                   | Bu et al., 2012               |
|            | Morphine      | Withdrawal              | Rhesus monkey Nacc                | Decrease in α5 subunit and increase in Ubiquitin C-terminal hydrolase L3                  | Bu et al., 2012               |
| Stimulants | Methamphetamine| 3–18 h                  | N27 dopaminergic cells            | Impaired proteasome activity                                                               | Lin et al., 2012              |
|            | Methamphetamine| Acute injection         | Rat striatum                      | Increase in Ubiquitin C-terminal hydrolase L1 and decrease in RN3 subunit                  | Iwazaki et al., 2006          |
|            | Methamphetamine| 24–48 h                 | Rat striatum and frontal cortex   | Transient decrease in 26S proteasome activity                                              | Dietrich et al., 2005         |
|            | Methamphetamine| 8 days                  | Rat frontal cortex                | Increase in Ubiquitin C-terminal hydrolase L1 and decrease in α1, α2 and regulatory 6A subunits | Faure et al., 2009            |

(Continued)
| Drug class | Drug          | Treatment | Cell type/Species                      | Molecular/cellular effects                                                                 | Reference             |
|------------|---------------|-----------|----------------------------------------|-------------------------------------------------------------------------------------------|-----------------------|
| Amphetamine | Amphetamine   | 7 days + withdrawal | Rat striatum PSD                     | UPS-dependent degradation of Shank and GKAP                                                 | Mao et al., 2009      |
| Cocaine    | Cocaine       | CPP       | Rat medial prefrontal cortex           | Increase in Ubiquitin-conjugating enzyme E2N, α2 and regulatory p45/SUG subunit            | Guan and Guan, 2013  |
| Cocaine    | Cocaine       | 24–48 h   | Rat striatum and frontal cortex        | Transient increase in 26S proteasome activity                                              | Dietrich et al., 2005|
| Cocaine    | Cocaine       | CPP       | Rat Nacc core                          | UPS-dependent degradation of NSF protein                                                   | Ren et al., 2013      |
| Ethanol    | Ethanol       | 5 days    | Mouse cortical neurons                 | Decrease in the mRNA of Ubiquitin-conjugating enzymes E2 and E3A, Ubiquitin specific protease 9, and 7 regulatory or catalytic subunits | Gutala et al., 2004  |
| Ethanol    | Ethanol       | 4 months, drinking water | Mouse cortex                         | Impairment of UPS activity associated with an increase in immunoproteasome subunits       | Pla et al., 2014      |
| Nicotine   | Nicotine      | 17 h      | HEK cells, rat cortical neurons         | Reduced ERAD-dependent degradation of α4β2 nicotinic acetylcholine receptors             | Govind et al., 2012  |
| Nicotine   | Nicotine      | 8 h       | Recombinant HELA cells                 | Reduced ERAD-dependent degradation of α3β4 nicotinic acetylcholine receptors             | Mazzo et al., 2013   |
| Nicotine   | Nicotine      | 14 days   | Rat prefrontal cortex                  | Increase in the mRNA of several Ubiquitin-conjugating enzymes, Ubiquitin proteases, and regulatory and catalytic subunits of the proteasome | Kane et al., 2004    |
| Nicotine   | Nicotine      | 14 days   | Rat medial basal hypothalamus          | Decrease in the mRNA of several Ubiquitin-conjugating enzymes and α subunits             | Kane et al., 2004    |
| Nicotine   | Nicotine      | 14 days   | Mouse dopaminergic neurons             | Increase in the mRNA of the E2 ubiquitin-conjugating enzyme E2J2, decrease in that of PSME2 regulatory subunit and Ubiquitin specific proteases 16 and 34 | Henley et al., 2013   |
| Nicotine   | Nicotine      | 24 h      | Mouse prefrontal cortex                | Inhibition of UPS associated with increased glutamate receptor subunits and PSD95        | Rezvani et al., 2007 |
| Cannabinoids | Δ9-THC      | 48 h      | Human astrocytes                       | Increase in the mRNA of Ubiquitin specific protease 3                                    | Bindukumar et al., 2008|
|            | HU-210        | 16 h      | Neuro-2A cells                         | UPS-dependent degradation of Rap1GAPIII resulting in neurite outgrowth                    | Jordan et al., 2005  |

that of ubiquitin and Ubiquitin-conjugating enzyme 7 increase in the white matter of the brain of alcoholic patients (Alexander-Kaufman et al., 2006; Kashem et al., 2007). Again at the mRNA level, chronic treatment of rats with nicotine produces an elevated expression of ubiquitin-conjugating enzymes, proteasome regulatory and catalytic subunits and DUBs in the prefrontal cortex whereas their level is decreased in the medial basal hypothalamus (Kane et al., 2004). Variations can be of opposite direction within a single cell type with for example an up-regulation of the E2 ubiquitin-conjugating enzyme E2J2 associated with the down-regulation of a proteasome regulatory subunit and two DUBs in mouse dopaminergic neurons chronically treated with nicotine (Henley et al., 2013). Finally an up-regulation of the DUB Ubiquitin specific protease 3 was observed in human astrocytes exposed for 48 h to Δ9-THC (tetra-hydro-cannabinol) (Bindukumar et al., 2008).
All drugs of abuse can thus affect the expression and abundance of key UPS proteins. However, the data reported above are only descriptive. Moreover, UPS components are affected differently depending on the drug type, its method of administration, the duration of the treatment and the cell type or brain region considered (Table 1). Complementary studies have also found that drugs of abuse modify the activity of the UPS in parallel with changes in the expression of its various components. Indeed morphine was demonstrated to inhibit the activity of the 20S proteasome in human neuroblastoma cells, with neuroprotective consequences (Rambhia et al., 2005). On the contrary, PKC-dependent inhibition of the UPS was linked to the autophagy-mediated toxicity of methamphetamine in dopaminergic neurons (Lin et al., 2012). In addition it has been proposed that the higher toxicity of methamphetamine compared to cocaine was due to its long inhibitory effect on proteasome activity (Dietrich et al., 2005). Finally, a recent study demonstrated that chronic ethanol induces toxicity in mice through a Toll-like receptor 4-dependent impairment of the UPS (Pla et al., 2014). This deleterious effect could depend on a shift in proteasome composition from classical to immuno-proteasome subunits, a phenomenon known to play a role in the neurotoxicity observed in neurodegenerative diseases, and on an increase in chymotrypsin-like and trypsin-like activities (Pla et al., 2014).

So far we have only described global changes in the composition and/or activity of the UPS associated with beneficial or deleterious effects on the functioning or survival of neurons. However, more subtle and finely regulated mechanisms need to be considered to explain the plasticity phenomena underlying the development of addiction-related behaviors. These mechanisms do not necessarily imply a global modification of UPS activity but rather the degradation of specific targets in precise cellular locations. Unfortunately fewer studies have focused more specifically on synaptic and/or signaling proteins degraded by the UPS in relation with the administration of drugs of abuse.

**UPS TARGETS INVOLVED IN DRUG-INDUCED PLASTICITY**

Drugs of abuse target receptors, channels and transporters located in the plasma membrane. However, membrane proteins are not typical proteasome substrates but are rather degraded in lysosomes. Proteasome-mediated degradation only occurs for misfolded membrane proteins through the ERAD (Endoplasmic reticulum-associated protein degradation) pathway before their export to the plasma membrane (Christianson and Ye, 2014) but ubiquitination can also modulate the degradation of membrane proteins after endocytosis by influencing their sorting to lysosomes through the ESCRT (endosomal sorting complexes required for transport) system (Macgurn et al., 2012). This phenomenon involves HECT (Homologous to the E6-AP Carboxy Terminus) E3 ligases and will not be discussed in detail here since it is proteasome-independent. However, it is worth mentioning that, since proteasome inhibitors cause the accumulation of ubiquitinated proteins and thus reduce the available pool of free ubiquitin, they can affect indirectly ubiquitin-dependent proteasome-independent processes such as sorting to lysosome (Mimnaugh et al., 1997).

Mu opioid (MOP) receptors play a role in the rewarding and reinforcing properties of opioids but also of most non-opioid abused drugs (Le Merrer et al., 2009). They are ubiquitinated following activation. Proteasome inhibitors increase their basal abundance and decrease agonist-induced down-regulation in recombinant cells (Chaturvedi et al., 2001). The increase in basal receptor expression following proteasome inhibition could be due to the blocking of the ERAD pathway whereas the reduction in agonist-induced down-regulation could result from the indirect effect of proteasome inhibitors on ubiquitin-dependent sorting to lysosomes. Indeed it was recently shown that the ubiquitination of the first intracellular loop of the MOP receptor facilitates its lysosomal degradation by promoting its transfer to intraluminal vesicles downstream of the ESCRT system (Hislop et al., 2011). It was also proposed that different translational forms of the receptor showed different sensitivities to the ERAD pathway because of additional ubiquitination sites (Song et al., 2009). Besides the MOP receptor, the nicotinic receptor is another example of drug target which has been shown to be regulated by the UPS. Here again the ERAD pathway seems to be involved and the subunit composition of pentameric nicotinic receptors has an influence on their sensitivity to this pathway (Govind et al., 2012; Mazzo et al., 2013).

UPS-dependent changes have also been identified downstream of receptor activation. In SH-SY5Y human neuroblastoma cells, long-term morphine treatment induces proteasome-dependent degradation of the Gβ subunit of heterotrimeric G proteins (Mouledous et al., 2005). This degradation could reduce G protein-coupled receptor signaling and restore the activity of effectors normally inhibited by Gβ subunits such as adenylyl cyclase. In the same cells, opioids have also been shown to induce the ubiquitination and degradation of regulator of G protein signaling 4 (RGS4), a protein that controls the duration of G protein signaling by acting as a GTPase accelerating protein (GAP) (Wang and Traynor, 2011). RGS4 is an unstable protein known to be subjected to the N-end rule pathway, a particular type of regulation based on the removal of the N-terminal methionine and the arginylation of the resulting N-terminal cysteine to promote ubiquitination and proteasome degradation. Its down-regulation affects the signaling of other G protein-coupled receptors present in the same cell. Overall, by regulating the abundance of several signaling molecules sensitive to opioid treatment, the UPS participates in the homeostatic processes involved in the development of opioid tolerance and dependence (Bailey and Connor, 2005; Christie, 2008). In mice, chronic morphine treatment induces a decrease in the total amount of ubiquitinated proteins in the striatum. In parallel, the heat-shock protein HSP70 was shown to be overexpressed, probably because of a lower ubiquitination rate (Yang et al., 2014). The higher expression of this protein could participate in the behavioral sensitization induced by morphine (Qin et al., 2013). However, the HSP70 cellular effect mediating this process is currently unknown. Besides changes in signaling, long-term drug treatment is known to affect neuronal structural plasticity (Robinson and Kolb, 2004). Small G proteins can influence cellular architecture and it is thus significant to note that, in neuro-2A cells, cannabinoids induce neurite outgrowth by activating the small G protein
Rap1 through the proteasome-dependent degradation of one of its GAP, Rap1GAP II (Jordan et al., 2005).

The neuronal adaptations described so far are homeostatic non-associative phenomena. They result from the direct activation of the drug target and its downstream signaling and are not sufficient to explain the associative processes involved in addiction. Similarly to classical forms of memory, drug addiction involves activity-dependent plasticity at excitatory synapses within neuronal circuits, notably those controlling motivated behaviors (Kauer and Malenka, 2007; Russo et al., 2010). Following drug administration, the UPS system regulates the abundance of several proteins at the glutamatergic synapse but very few studies have identified these proteasome targets. In the case of opioids, an increase in ubiquitinated proteins in the synaptosomal fraction of the mouse Nacc was observed following morphine conditioning (Massaly et al., 2013) but the identity of the UPS targeted proteins was not reported. So far, the only glutamate-related proteins shown to be degraded by the proteasome following chronic morphine treatment are glutamate transporters EAAC1, GLSAT, and GLT-1 but these changes were observed in the rat spinal cord and were related to analgesic tolerance rather than addiction (Yang et al., 2008a,b). Concerning nicotine, one study addressed the effect of its intraperitoneal injection in mice on the expression of synaptic proteins (Rezvani et al., 2007). It suggested that the observed increase in the amount of GluR1 \( \alpha \)-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunits, NR2A NMDA receptor subunits, metabotropic receptor mGluR1, and PSD95 (a scaffolding protein of the PSD), but also the decrease in the quantity of Shank (another scaffolding protein), were due to an inhibition of proteasome activity. The exposure to stimulants was also reported to have UPS-dependent synaptic effects. NAC1 (nucleus accumbens-associated protein 1), the product of an immediate early gene up-regulated by psychostimulants, takes part in the recruitment of the proteasome to the PSD by interacting with Cullin-based E3 ubiquitin ligases and the 19S ATPase subunit Mov34 (Shen et al., 2007). The UPS could also contribute to the phenomenon of synaptic scaling that is observed in the Nacc following cocaine withdrawal and results from the addition of AMPA receptors to the synapse (Sun and Wolf, 2009). UPS-dependent synaptic changes in the striatum have been shown to contribute to the behavioral sensitization induced by repeated amphetamine injections in rats. Contrarily to acute nicotine injection, chronic amphetamine treatment produced a decrease in NMDA receptor subunits and anchoring proteins in the PSD. Only Shank and GKAP (guanylate-kinase-associated protein) were ubiquitinated and it was proposed that the degradation of these important anchoring proteins indirectly leads to a loss of PSD95 and NR1 and NR2B subunits of the NMDA receptor at the synapse (Mao et al., 2009). Finally, the retrieval of cocaine place preference in rats has been shown to result in an increase in protein poly-ubiquitination in the core of the Nacc, and in particular in the degradation of NSF (N-ethylmaleimide-sensitive fusion), a protein of the PSD involved in synaptic plasticity (Ren et al., 2013). In conclusion, the UPS is involved in the synaptic plasticity that underlies some of the behavioral adaptations to drug exposure. However, the molecular details are still poorly known and will probably depend on the drug type, the location of the synapse in the neuronal circuit and the phase of the addiction process under study. It is thus critical to implement studies to establish direct causal relationship between the degradation of neuronal proteins by the UPS in a particular brain region and a given addiction-related behavior.

**UPS AND ADDICTION-RELATED BEHAVIORS**

Few studies have assessed the role of protein degradation by the proteasome in drug-related behaviors. Recently we found that UPS function in the Nacc is crucial in several types of opioid-induced behaviors (Massaly et al., 2013). Our goal was to assess the role of protein degradation by the proteasome in the development of drug seeking behaviors and the motivation to obtain opioids. By using proteasome inhibitors our study demonstrated a clear role of the UPS in the Nacc during acquisition of non-operant tasks, namely CPP and context-dependent locomotor sensitization in mice. Intra-Nacc proteasome inhibitors also prevented the acquisition of operant tasks in mice (intra-VTA self-administration) and rats (intra-venous self-administration). However, these behavioral paradigms do not enable us to clearly discriminate between an effect of proteasome inhibitors on drug-induced memory and on non-associative drug effects. The behavioral sensitization procedure can be implemented in a context-dependent or -independent way (Valjent et al., 2006). Figures 2A–C shows the comparison between the effects of proteasome inhibition in a context-dependent (Massaly et al., 2013) and a context-independent paradigm. In both experiments mice were submitted to 5 daily morphine injections followed by a 2 day withdrawal period. On day 1 basal horizontal activity was measured during 1 h directly after i.p. morphine injection (Figures 2B,C, empty bars). On days 2, 3, 4, and 5 mice received intra-Nacc injection of DMSO or the proteasome inhibitor lactacystin 1 h prior to i.p. morphine treatment and were then directly placed in their home cage to prevent association between drug and cues present in activity boxes (context-independent, Figure 2C) or in activity boxes (context-dependent, Figure 2B). Three days after the last opioid treatment, animals were challenged with an i.p. morphine injection and locomotor activity was measured during 1 h to assess behavioral sensitization. Control groups showed a significant locomotor sensitization on day 8 (Figures 1C, 2B, DMSO group). Lactacystin injections prevented behavioral sensitization only in the context-dependent procedure (Figure 2B). It thus appears that the UPS in the Nacc is not necessary for the development of behavioral sensitization when this adaptation is context-independent (Figures 2A–C, refer to (Massaly et al., 2013) for details). This result, together with the fact that intra-Nacc injection of proteasome inhibitors prevents the consolidation of morphine place preference, strongly suggests that UPS activity in the Nacc is involved in drug-context association rather than non-associative motivational effects of opioids. However, this distinction might not be true for each type of drug of abuse and in particular for stimulants. Indeed, proteasome inhibitors have been shown to inhibit the development of behavioral sensitization to amphetamine after intra-Nacc injection in rats in a context-independent paradigm (Mao et al., 2009).
FIGURE 2 | UPS involvement in behavioral sensitization and reconsolidation of morphine place preference. (A) Schematic representation of the protocol followed in context-dependent and -independent locomotor sensitization. The morphine dose was 10 mg/kg. (B) UPS inhibition blocks the acquisition of behavioral sensitization when a context-dependent paradigm is used (lactacystin 100 pmol in 0.5 μl per side: n = 8 and DMSO: n = 11), (C) whereas it does not affect this drug-adaptation in a context-independent procedure (lactacystin: n = 6 and DMSO: n = 8). Data are expressed in number of beam breaks ± SEM during a 1 h session.
Consolidation is the process by which stable long-term memories are formed following a learning session. Reconsolidation refers to the fact that the memory trace can return to an active labile state after recall (Alberini and Ledoux, 2013). Interfering with this process could thus offer a way to erase drug-context association with important therapeutic consequences. If lactacystin is injected in the Nacc before a new drug-compartment association performed 1 week after the last morphine place preference conditioning (Massaly et al., 2013, Figure 2D), mice do not display any place preference for the morphine compartment on the following day, contrarily to the DMSO control group (Figure 2E). The UPS in the Nacc thus seems to be involved in reconsolidation of place preference induced by morphine. Our conclusions concerning the involvement of the UPS in consolidation and reconsolidation of drug-associated memories are only partly consistent with those of the only other study examining this question (Ren et al., 2013). Ren et al. found that inhibiting UPS activity in the Nacc interfered with drug-reward memories using cocaine CPP in rats. However, in their model, proteasome inhibitors blocked CPP extinction when injected following each extinction session but were not efficient on memory consolidation during the learning phase. Moreover, they did not interfere directly with memory reconsolidation following a reactivation session but counteracted the inhibitory effect of protein synthesis inhibition on this process. These apparent discrepancies are likely due to many differences in experimental conditions between the two studies: animal model (rats vs. mice), drug type (cocaine vs. morphine), conditioning procedure (4 drug/saline injections over 8 days vs. 3 injections over 3 days), timing of injection of proteasome inhibitors (before vs. after memory reactivation), method of induction of memory reconsolidation (reactivation in the absence vs. in the presence of drug). Taken together, the two studies confirm that the UPS in the Nacc plays a key role in drug-reward memories although further work is needed to fully understand under which exact circumstances it is recruited.

In conclusion, even if some discrepancies can be observed between studies depending on the model under investigation, it appears that the UPS plays a role in drug-related behaviors and the adaptation to the exposure to drugs of abuse. Future work will certainly bring us new evidence to complete the picture of the involvement of proteasome-dependent protein degradation in the brain during addiction.

**FUTURE DIRECTIONS**

It is clear from the studies reviewed here that the UPS plays an essential role in neuronal plasticity associated with long-term exposure to drugs of abuse. However, the UPS is involved in so many cellular processes that we are still a long way from understanding its specific contribution to each aspect of drug use and abuse. Several outstanding questions need to be addressed to achieve this goal. What are the most significant cellular targets of the UPS during neuronal plasticity associated with drug addiction? So far, studies have focused on synaptic and signaling proteins but other types of proteins, such as for example transcription factors, are mandatory for enduring neuronal plasticity and could be regulated directly or indirectly by UPS-dependent processes (Carle et al., 2007; Dong et al., 2008). Where does the regulation take place? All the behavioral studies reported here focused on the Nacc but different UPS-dependent changes will probably occur depending on the brain region. Also alterations in protein content will vary according to the type of plasticity occurring in each individual neuron or synapse. When does the protein need to be degraded? Different UPS targets will be concerned depending on the phase of the addiction process. For example changes appearing along the course of drug administration will probably differ from those resulting from withdrawal. Why is a UPS-dependent regulation occurring? In particular it will be important to distinguish homeostatic regulations involved in non-associative tolerance or sensitization from more integrated plasticity phenomena responsible for associative context-dependent aspects of addiction. How are the proteins targeted to the proteasome? Identifying the mechanism by which each important UPS substrate is targeted to the proteasome (post-translational modification preceding ubiquitination, type of E3 ligase...) will offer opportunities to control addiction-related processes more specifically than by blocking the catalytic activity of the proteasome. Many technical limitations may prevent us from answering fully to these questions but the link between the control of protein expression through UPS-dependent degradation and plastic changes involved in addiction clearly deserves further investigation.

**REFERENCES**

Alberini, C. M., and Ledoux, J. E. (2013). Memory reconsolidation. Curr. Biol. 23, R746–R750. doi: 10.1016/j.cub.2013.06.046

Alexander-Kaufman, K., James, G., Sheedy, D., Harper, C., and Matsumoto, I. (2006). Differential protein expression in the prefrontal white matter of human alcoholics: a proteomics study. Mol. Psychiatry 11, 56–65. doi: 10.1038/sj.mp.4001741

Artinian, J., McGauran, A. M., De Jaeger, X., Mouledous, L., Frances, B., and Roulet, P. (2008). Protein degradation, as with protein synthesis, is required during not only long-term spatial memory consolidation but also reconsolidation. Eur. J. Neurosci. 27, 3009–3019. doi: 10.1111/j.1460-9588.2008.06262.x

Bailey, C. P., and Connor, M. (2005). Opioids: cellular mechanisms of tolerance and physical dependence. Curr. Opin. Pharmacol. 5, 60–68. doi: 10.1016/j.coph.2004.08.012

Bindukumar, B., Mahajan, S. D., Reynolds, I. L., Hu, Z., Sykes, D. E., Aalinkel, R., et al. (2008). Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes. Brain Res. 1191, 1–11. doi: 10.1016/j.brainres.2007.10.062
Bingt, B., and Sheng, M. (2011). Deconstruction for reconstruction: the role of proteolysis in neural plasticity and disease. Neuron 69, 22–32. doi: 10.1016/j.neuron.2010.11.006

Bu, Q., Yang, Y., Yan, G., Hu, Z., Hu, C., Duan, J., et al. (2012). Proteomic analysis of the mushroom bodies in rhesus monkeys of morphine dependence and withdrawal intervention. J. Proteomics 75, 1330–1342. doi: 10.1016/j.jprot.2011.11.008

Carle, T. L., Ohnishi, Y. N., Ohnishi, Y. H., Alibhai, I. N., Wilkinson, M. B., Kumar, A., et al. (2007). Proteasome-dependent and -independent mechanisms for FoxB destabilization: identification of FoxB degron domains and implications for DeltaFoxB stability. Eur. J. Neurosci. 25, 3009–3019. doi: 10.1111/j.1460-9568.2007.05375.x

Chaturvedi, K., Bandari, P., Chinen, N., and Howells, R. D. (2001). Proteasome involvement in agonist-induced down-regulation of mu and delta opioid receptors. J. Biol. Chem. 276, 12345–12355. doi: 10.1074/jbc.M008054200

Christianson, J. C., and Ye, Y. (2004). Cleaning up in the endoplasmic reticulum: ubiquitin in charge. Nat. Struct. Mol. Biol. 21, 325–335. doi: 10.1038/nsmb.2793

Christie, M. J. (2008). Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br. J. Pharmacol. 154, 384–396. doi: 10.1038/bjp.2008.100

Ciechanover, A. (2005). Proteolysis: from the lysosome to ubiquitin and the ubiquitin-proteasome pathway and synaptic plasticity. Ann. Rev. Cell Dev. Biol. 21, 182–206. doi: 10.1146/annurev.cellbio-100108-152314

Hislop, J. N., Henry, A. G., and Von Zastrow, M. (2011). Ubiquitination in the first cytoplasmic loop of mu-opioid receptors reveals a hierarchical mechanism of lysosomal down-regulation. J. Biol. Chem. 286, 40193–40204. doi: 10.1074/jbc.M111.288555

Huh, S. E., Malenka, R. C., and Nestler, E. J. (2006). Neural mechanisms of addiction: the role of reward-related learning and memory. Annu. Rev. Neurosci. 29, 565–598. doi: 10.1146/annurev.neuro.29.051605.113009

Iwazaki, T., McGregor, I. S., and Matsumoto, I. (2006). Protein expression profile in the striatum of acute methamphetamine-treated rats. Brain Res. 1097, 19–25. doi: 10.1016/j.brainres.2006.04.052

Jaroje, T. I., and Helmstetter, F. I. (2014). Protein degradation and protein synthesis in long-term memory formation. Front. Mol. Neurosci. 7:61. doi: 10.3389/fnmol.2014.00061

Jaroje, T. J., Werner, C. T., Kwapis, J. L., and Helmstetter, F. J. (2011). Activity-dependent protein degradation is critical for the formation and stability of fear memory in the amygdala. PLoS ONE 6:e24349. doi: 10.1371/journal.pone.0024349

Jordan, J. D., He, J. C., Eungdamrong, N. J., Gomes, L., Ali, W., Nguyen, T., et al. (2005). Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through G(alpha)/opioid receptor triggered proteasomal degradation of Rap1GAP. J. Biol. Chem. 280, 11413–11421. doi: 10.1074/jbc.M411521200

Kane, J. K., Konu, O., Ma, J. Z., and Li, M. D. (2004). Nicotine coregulates multiple pathways involved in protein modification/degradation in rat brain. Brain Res. Mol. Brain Res. 132, 181–191. doi: 10.1016/j.molbrainres.2004.09.010

Kashem, M. A., James, G., Harper, C., Wilce, P., and Matsumoto, I. (2007). Differential protein expression in the corpus callosum (splenum) of human alcoholics: a proteomics study. Neurochem. Int. 50, 450–459. doi: 10.1016/j.neuint.2006.10.009

Kauer, J. A., and Malenka, R. C. (2007). Synaptic plasticity and addiction. Nat. Rev. Neurosci. 8, 844–858. doi: 10.1038/nrn2234

Kim, S. Y., Chudapongse, N., Lee, S. M., Levin, M. C., Oh, J. T., Park, H. J., et al. (2005). Proteomic analysis of phosphotyrosin proteins in morphine-dependent rat brains. Brain Res. Mol. Brain Res. 133, 58–70. doi: 10.1016/j.molbrainres.2004.09.018

Kobessy, F. H., Zhang, Z., Sadasivan, S., Gold, M. S., and Wang, K. K. (2009). Methods in drug abuse neuroproteomics: methamphetamine psychoproteome. Methods Mol. Biol. 566, 217–228. doi: 10.1007/978-1-59745-562-6_15

Le Merrer, I., Becker, J. A., Befort, K., and Kieffer, B. L. (2009). Reward processing by the opioid system in the brain. Physiol. Rev. 89, 1379–1412. doi: 10.1152/physrev.00005.2009

Lee, S. H., Choi, J. H., Lee, N., Lee, H. R., Kim, J. I., Yu, N. K., et al. (2008). Synthetic protein degradation underlies destabilization of retrieved fear memory. Science 319, 1253–1256. doi: 10.1016/j.neuroscience.2005.01.018

Li, K. W., Jimenez, C. R., van Der Schors, R. C., Hornshaw, M. P., Schoffelmeer, A. N., and Smit, A. B. (2006). Intermittent administration of morphine alters protein expression in rat nucleus accumbens. Proteomics 6, 2003–2008. doi: 10.1002/pmc.200500045

Li, Q., Xiao, Z., Zhong, L. J., Yang, H. Y., Wang, Q., and Pu, X. P. (2009). Effects of chronic morphine treatment on protein expression in rat dorsal root ganglia. Eur. J. Pharmacol. 612, 21–28. doi: 10.1016/j.ejphar.2009.03.049

Lin, M., Chandramani-Shivalingappa, P., Jin, H., Ghosh, A., Anantharam, V., Ali, S., et al. (2012). Methamphetamine-induced neurotoxicity linked to ubiquitin-proteosome system dysfunction and autophagy-related changes that can be modulated by protein kinase C delta in dopaminergic neuronal cells. Neuroscience 210, 308–332. doi: 10.1016/j.neuroscience.2012.03.004

Lin, X., Wang, Q., Cheng, Y., Ji, J., and Yu, L. C. (2011). Changes of protein expression in the amygdala during the process of morphine-induced conditioned place preference in rats. Behav. Brain Res. 221, 197–206. doi: 10.1016/j.bbr.2011.03.002

Liu, S., Chen, Z. I. (2011). Expanding role of ubiquitination in NF-kappaB signaling. Cell Res. 21, 6–21. doi: 10.1038/cr.2010.170

Lopez-Salon, M., Alonso, M. A., Vianna, M. R., Viola, H., Mello E Souza, T., Izquierdo, I., et al. (2001). The ubiquitin-proteasome cascade is required for mammalian long-term memory formation. Eur. J. Neurosci. 14, 1820–1826. doi: 10.1046/j.0953-8166.2001.01806.x

Mabb, A. M., and Ehlers, M. D. (2010). Ubiquitination in postsynaptic function and plasticity. Annu. Rev. Cell Dev. Biol. 26, 179–210. doi: 10.1146/annurev-cellbio-100109-104129
Mazzu, F., Pistillo, F., Grazioso, G., Clementi, F., Borgese, N., Gotti, C., et al. (2009). Stability of surface NMDA receptors controls synaptic and behavioral adaptations to amphetamine. Nat. Neurosci. 12, 602–610. doi: 10.1038/nn.2300

Massaly, N., Dahan, L., Baudonnat, M., Hovnanian, C., Rekik, K., Solinas, M., et al. (2013). Involvement of protein degradation by the ubiquitin proteasome system in opiate addictive behaviors. Neuropsychopharmacology 38, 596–604. doi: 10.1038/npp.2012.217

Mazlo, F., Pistillo, F., Grazioso, G., Clementi, F., Borgese, N., Gotti, C., et al. (2013). Nicotine-modulated subunit stoichiometry affects stability and trafficking of alpha3beta4 nicotinic receptor. J. Neurosci. 33, 12316–12328. doi: 10.1523/JNEUROSCI.2393-13.2013

Milton, A. L., and Everitt, B. J. (2012). The persistence of maladaptive memory: addiction, drug memories and anti-relapse treatments. Neurosci. Biobehav. Rev. 36, 1119–1139. doi: 10.1016/j.neubiorev.2012.01.002

Mimnaugh, E. G., Chen, H. Y., Davie, J. R., Celis, E. J., and Neckers, L. (1997). Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers: effects on replication, transcription, translation, and the cellular stress response. Biochemistry 36, 14418–14429. doi: 10.1021/bi970998k

Mouledous, L., Neasta, J., Uttenweiler-Joseph, S., Stella, A., Matondo, M., Corbani, M., et al. (2005). Long-term morphine treatment enhances proteasome-dependent degradation of G beta in human neuroblastoma SH-SYSY cells: correlation with onset of adenylylcyclosation sensitization. Mol. Pharmacol. 68, 467–476. doi: 10.1124/mol.105.013391

Neasta, J., Uttenweiler-Joseph, S., Chauki, K., Monsarrat, B., Meunier, J. C., and Mouledous, L. (2006). Effect of long-term exposure of SH-SY5Y cells to morphone: a whole cell proteomic analysis. Proteome Sci. 4:23. doi: 10.1186/1477-5956-4-23

Patrick, G. N. (2006). Synapse formation and plasticity: recent insights from the perspective of the ubiquitin proteasome system. Curr. Opin. Neurobiol. 16, 90–94. doi: 10.1016/j.conb.2006.01.007

Pla, A., Pascual, M., Renau-Piqueras, J., and Guerri, C. (2014). TLRA mediates the impairment of ubiquitin-proteasome and autophagy-lysosome pathways induced by ethanol treatment in brain. Cell Death Dis. 5:e1066. doi: 10.1038/cddis.2014.46

Qin, W. J., Wang, Y. T., Zhang, M., Wen, R. T., Liu, Q., Li, Y. L., et al. (2013). Molecular chaperone heat shock protein 70 participates in the labile state of the ubiquitin-proteasome complex is neuroprotective. Med. Sci. Monit. 11, BR386–BR396.

Reis, D. S., Jeramie, T. I., and Helmstetter, F. J. (2013). Memory formation for trace fear conditioning requires ubiquitin-proteasome mediated protein degradation in the prefrontal cortex. Front. Behav. Neurosci. 7:150. doi: 10.3389/fnbeh.2013.00150

Ren, Z. Y., Liu, M. M., Xue, Y. X., Ding, Z. B., Xue, L. F., Zhai, S. D., et al. (2013). A critical role for protein degradation in the nucleus accumbens core in cocaine reward memory. Neuropharmacology 38, 778–790. doi: 10.1038/npp.2012.243

Rezvani, K., Teng, Y., Shim, D., and De Biasi, M. (2007). Nicotine regulates multiple synaptic proteins by inhibiting proteasomal activity. J. Neurosci. 27, 10508–10519. doi: 10.1523/JNEUROSCI.3533-07.2007

Robinson, T. E., and Kolb, B. (2004). Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology 47(Suppl. 1), 33–46. doi: 10.1016/j.neuropharm.2004.06.025

Rodriguez-Ortiz, C. J., Balderas, I., Saucedo-Alquicira, F., Cruz-Castaneda, P., and Bermudez-Rattoni, F. (2011). Long-term aversive taste memory requires insular and amygdala protein degradation. Neurobiol. Learn. Mem. 95, 311–315. doi: 10.1016/j.nlm.2010.12.010

Russo, S. J., Dietz, D. M., Dumitriu, D., Morrison, J. H., Malenka, R. C., and Nestler, E. J. (2010). The addicted synapse: mechanisms of synaptic and structural plasticity in nucleus accumbens. Trends Neurosci. 33, 267–276. doi: 10.1016/j.tins.2010.02.002

Shen, H., Kourtula, L., Champaiaux, N., Toda, S., Lalumiere, R., Vallone, J., et al. (2007). NAC1 regulates the recruitment of the proteasome complex into dendritic spines. J. Neurosci. 27, 8903–8913. doi: 10.1523/JNEUROSCI.1571-07.2007

Song, K. Y., Choi, H. S., Hwang, C. K., Kim, C. S., Law, P. Y., Wei, L. N., et al. (2009). Differential use of an in-frame translation initiation codon regulates human mu opioid receptor (OPRM1). Cell. Mol. Life Sci. 66, 2933–2942. doi: 10.1007/s00018-009-0882-7

Sun, X., and Wolf, M. E. (2009). Nucleus accumbens neurons exhibit synaptic scaling that is occluded by repeated dopamine pre-exposure. Eur. J. Neurosci. 30, 539–550. doi: 10.1111/j.1460-9568.2009.06852.x

Valjent, E., Corvol, J. C., Trzaskos, J. M., Girault, J. A., and Herve, D. (2006). Role of the ERK pathway in psychostimulant-induced locomotor sensitization. BMC Neurosci. 7:20. doi: 10.1186/1471-2202-7-20

Yang, Q., and Traynor, J. R. (2011). Opioid-induced Down-Regulation of RGS4: role of ubiquitination and implications for receptor cross-talk. J. Biol. Chem. 286, 7854–7864. doi: 10.1074/jbc.M110.160911

Woo, C. H., Le, N. T., Shishido, T., Chang, E., Lee, H., Heo, K. S., et al. (2010). Novel role of C terminus of Hsc70-interacting protein (CHIP) ubiquitin ligase on inheg cardiac apoptosis and dysfunction via regulating ERK5-mediated degradation of inducible Camp early repressor. Faseb J. 24, 4917–4928. doi: 10.1096/fj.10-162636

Yang, H. Y., Pu, X. P., and Liu, Y. (2014). Chronic morphine treatment induces over-expression of HSP70 in mice striatum related with abnormal ubiquitin-proteasome degradation. Drug Alcohol Depend. 139, 53–59. doi: 10.1016/j.drugalcdep.2014.03.005

Yang, L., Wang, S., Lim, G., Sung, B., Zeng, Q., and Mao, J. (2008a). Inhibition of the ubiquitin-proteasome activity prevents glutamate transporter degradation and morphine tolerance. Pain 140, 472–478. doi: 10.1016/j.pain.2008.09.028

Yang, L., Wang, S., Sung, B., Lim, G., and Mao, J. (2008b). Morphine induces ubiquitin-proteasome activity and glutamate transporter degradation. J. Biol. Chem. 283, 21703–21713. doi: 10.1074/jbc.M800809.2020

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 29 October 2014; accepted: 08 December 2014; published online: 06 January 2015.

Citation: Massaly N, Francès B and Moulédous L (2015) Roles of the ubiquitin proteasome and drug abuse system in opiate addictive behaviors. Front. Mol. Neurosci. 7:99. doi: 10.3389/fnmol.2014.00999

This article was submitted to the journal Frontiers in Molecular Neuroscience.

Copyright © 2015 Massaly, Francès and Moulédous. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.